FI843716A7 - Pyridiiniliukoista uutetta ja puhdistettua, myrkyttömäksi tehtyä endotoksiinia sisältävä koostumus ja sen käyttö. - Google Patents

Pyridiiniliukoista uutetta ja puhdistettua, myrkyttömäksi tehtyä endotoksiinia sisältävä koostumus ja sen käyttö. Download PDF

Info

Publication number
FI843716A7
FI843716A7 FI843716A FI843716A FI843716A7 FI 843716 A7 FI843716 A7 FI 843716A7 FI 843716 A FI843716 A FI 843716A FI 843716 A FI843716 A FI 843716A FI 843716 A7 FI843716 A7 FI 843716A7
Authority
FI
Finland
Prior art keywords
purified
composition containing
soluble extract
containing pyridine
detoxified endotoxin
Prior art date
Application number
FI843716A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI843716L (fi
FI843716A0 (fi
Inventor
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FI843716A0 publication Critical patent/FI843716A0/fi
Publication of FI843716L publication Critical patent/FI843716L/fi
Publication of FI843716A7 publication Critical patent/FI843716A7/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806Antigenic peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FI843716A 1983-09-23 1984-09-21 Pyridiiniliukoista uutetta ja puhdistettua, myrkyttömäksi tehtyä endotoksiinia sisältävä koostumus ja sen käyttö. FI843716A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use

Publications (3)

Publication Number Publication Date
FI843716A0 FI843716A0 (fi) 1984-09-21
FI843716L FI843716L (fi) 1985-03-24
FI843716A7 true FI843716A7 (fi) 1985-03-24

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
FI843716A FI843716A7 (fi) 1983-09-23 1984-09-21 Pyridiiniliukoista uutetta ja puhdistettua, myrkyttömäksi tehtyä endotoksiinia sisältävä koostumus ja sen käyttö.

Country Status (23)

Country Link
US (1) US4663306A (enExample)
JP (1) JPS60120817A (enExample)
KR (1) KR870000843B1 (enExample)
AT (1) AT385659B (enExample)
AU (1) AU566234B2 (enExample)
BE (1) BE900650A (enExample)
CA (1) CA1244765A (enExample)
CH (1) CH664897A5 (enExample)
DE (1) DE3434766C2 (enExample)
DK (1) DK446684A (enExample)
ES (1) ES8608872A1 (enExample)
FI (1) FI843716A7 (enExample)
FR (1) FR2552326B1 (enExample)
GB (1) GB2149301B (enExample)
HU (1) HU192585B (enExample)
IL (1) IL73034A (enExample)
IN (1) IN157240B (enExample)
IT (1) IT1179444B (enExample)
NL (1) NL8402902A (enExample)
NO (1) NO843776L (enExample)
NZ (1) NZ209635A (enExample)
SE (1) SE8404707L (enExample)
ZA (1) ZA847405B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
EP0714305B1 (en) * 1993-08-27 2001-12-19 Vetrepharm, Inc. Composition and method for stimulation of reproductive performance
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
DK1003525T3 (da) 1997-08-05 2003-03-24 Bioniche Life Sciences Inc Præparat og fremgangsmåde til regulering af celleproliferation og celledød
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
EP1097715A4 (en) * 1998-07-16 2004-12-29 Hayashi Akira PREPARATIONS FOR ANTICANCER IMMUNOTHERAPY COMPRISING A BACTERIAL SOMATIC COMPONENT AS AN ACTIVE INGREDIENT
HUP0300627A3 (en) * 1999-12-13 2005-11-28 Bioniche Life Sciences Inc Bel Therapeutically useful synthetic oligonucleotides
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US6632647B2 (en) * 2000-07-11 2003-10-14 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis against organ fibrosis
AU2002236215B2 (en) * 2002-03-05 2008-03-06 Cell-Medicine, Inc. Solidified tissue immunological adjuvant
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
US20060127518A1 (en) * 2003-09-05 2006-06-15 Shenyang Sunbellcom Bio-Pharmaceutical Co. Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
PL3158054T3 (pl) 2014-06-17 2025-07-21 Crown Laboratories, Inc. Bakterie zmodyfikowane genetycznie i sposoby modyfikacji genetycznej bakterii
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
US20210040055A1 (en) * 2017-08-17 2021-02-11 University Of Delaware Furan based compositions and methods of making thereof
US12102710B2 (en) 2020-06-23 2024-10-01 Crown Laboratories, Inc. Probiotic skin formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (enExample) * 1972-06-20 1973-12-27
FR2269962B1 (enExample) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白wenac及びその製造法
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism

Also Published As

Publication number Publication date
SE8404707L (sv) 1985-03-24
CA1244765A (en) 1988-11-15
AT385659B (de) 1988-05-10
GB2149301A (en) 1985-06-12
BE900650A (fr) 1985-03-21
ES536167A0 (es) 1986-07-16
DE3434766C2 (de) 1987-05-14
NO843776L (no) 1985-03-25
FI843716L (fi) 1985-03-24
AU566234B2 (en) 1987-10-15
US4663306A (en) 1987-05-05
CH664897A5 (de) 1988-04-15
SE8404707D0 (sv) 1984-09-20
ZA847405B (en) 1985-05-29
FI843716A0 (fi) 1984-09-21
DK446684A (da) 1985-03-24
DK446684D0 (da) 1984-09-19
IN157240B (enExample) 1986-02-15
NL8402902A (nl) 1985-04-16
DE3434766A1 (de) 1986-04-30
HU192585B (en) 1987-06-29
ES8608872A1 (es) 1986-07-16
GB8423993D0 (en) 1984-10-31
NZ209635A (en) 1989-01-27
IL73034A (en) 1988-11-15
AU3340084A (en) 1985-03-28
KR870000843B1 (ko) 1987-04-25
HUT35521A (en) 1985-07-29
IT1179444B (it) 1987-09-16
FR2552326B1 (fr) 1988-05-13
IT8448894A0 (it) 1984-09-24
ATA302384A (de) 1987-10-15
FR2552326A1 (fr) 1985-03-29
JPS60120817A (ja) 1985-06-28
KR850002404A (ko) 1985-05-13
JPS6254775B2 (enExample) 1987-11-17
GB2149301B (en) 1988-06-22

Similar Documents

Publication Publication Date Title
FI843716A7 (fi) Pyridiiniliukoista uutetta ja puhdistettua, myrkyttömäksi tehtyä endotoksiinia sisältävä koostumus ja sen käyttö.
FI875220A7 (fi) Mikrobeja tuhoavia proteiineja, niitä sisältäviä koostumuksia ja niiden käyttö.
DE3685409D1 (de) Antitumorzusammensetzung.
FI865037A0 (fi) Mikrobicida kompositioner.
FI864371L (fi) Tvaolkomposition.
DE3773631D1 (de) Polyaethylen-zusammensetzung.
FI851120A7 (fi) Syklosporiini, sen valmistus ja käyttö.
FI844562A0 (fi) Maetanordning foer metaboliska storheter anslutbar till en respirator.
FI830719A7 (fi) Uudet organopolysiloksaanit, niiden valmistusmenetelmät ja näiden organopolysiloksaanien käyttö.
DE3585704D1 (de) Thermoplastische-elastomere-zusammensetzung.
FI883837L (fi) Aoksjuka foerhindrande komposition.
FI831457A7 (fi) 1-sulfo-2-atsetidinon-johdannaiset, niiden valmistus ja käyttö.
KR880701523A (ko) N,n-디알킬알칸아미드로 되는 조성물 및 그 용도
FI830984A7 (fi) Uusi DNA ja sen käyttö.
FI863061L (fi) Tvaolkomposition.
DE3681504D1 (de) Polierzusammensetzung.
DE3675752D1 (de) Konservierungsmittelzusammensetzung.
DE3684003D1 (de) Propylen-polymer-zusammensetzung.
DE3684626D1 (de) Schmerzstillende zusammensetzung.
FI873905A7 (fi) Terapeuttinen koostumus ja menetelmä.
DE3583866D1 (de) Kompositmasse.
FI821287A7 (fi) Analgeettiset koostumukset ja niiden käyttötavat.
DE3779951D1 (de) Klebrigmachende zusammensetzung.
IT8645751A0 (it) Cavatappi tascabile.
DE3686740D1 (de) Einkomponenthaertbare zusammensetzung.

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: RIBI IMMUNOCHEM RESEARCH, INC.